JPWO2020165181A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020165181A5
JPWO2020165181A5 JP2021547154A JP2021547154A JPWO2020165181A5 JP WO2020165181 A5 JPWO2020165181 A5 JP WO2020165181A5 JP 2021547154 A JP2021547154 A JP 2021547154A JP 2021547154 A JP2021547154 A JP 2021547154A JP WO2020165181 A5 JPWO2020165181 A5 JP WO2020165181A5
Authority
JP
Japan
Prior art keywords
erdafitinib
cancer
specifically
daily
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521173A (ja
JP2022521173A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/053490 external-priority patent/WO2020165181A1/en
Publication of JP2022521173A publication Critical patent/JP2022521173A/ja
Publication of JPWO2020165181A5 publication Critical patent/JPWO2020165181A5/ja
Publication of JP2022521173A5 publication Critical patent/JP2022521173A5/ja
Priority to JP2025162216A priority Critical patent/JP2026016402A/ja
Withdrawn legal-status Critical Current

Links

JP2021547154A 2019-02-12 2020-02-11 癌治療 Withdrawn JP2022521173A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162216A JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19156806.2 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162216A Division JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Publications (3)

Publication Number Publication Date
JP2022521173A JP2022521173A (ja) 2022-04-06
JPWO2020165181A5 true JPWO2020165181A5 (https=) 2023-02-21
JP2022521173A5 JP2022521173A5 (https=) 2023-02-21

Family

ID=69467563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547154A Withdrawn JP2022521173A (ja) 2019-02-12 2020-02-11 癌治療
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162216A Pending JP2026016402A (ja) 2019-02-12 2025-09-29 癌治療

Country Status (16)

Country Link
US (1) US20220168298A1 (https=)
EP (1) EP3923942A1 (https=)
JP (2) JP2022521173A (https=)
KR (1) KR20210126654A (https=)
CN (1) CN113423402A (https=)
AU (1) AU2020223467B2 (https=)
BR (1) BR112021015686A2 (https=)
CA (1) CA3126959A1 (https=)
IL (1) IL285466A (https=)
JO (1) JOP20210216A1 (https=)
MA (1) MA54932A (https=)
MX (1) MX2021009670A (https=)
PH (1) PH12021551949A1 (https=)
SG (1) SG11202107850VA (https=)
TW (1) TWI863962B (https=)
WO (1) WO2020165181A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063516A1 (en) * 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
AU2016341445B2 (en) * 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Similar Documents

Publication Publication Date Title
EP4337191B1 (en) Egfr inhibitor for the treatment of head and neck cancer
CN113244209A (zh) 柠檬酸铁在治疗慢性肾脏疾病患者中的应用
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2020505425A5 (https=)
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2014513705A (ja) 進行性固形腫瘍の治療方法
TW201906633A (zh) 用於增進癌症化學療效之組合物及方法
TW201907916A (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
KR20240158972A (ko) 소세포 폐암의 치료 방법
JP2021063014A (ja) 白血病治療薬
JPWO2020165181A5 (https=)
US20230038138A1 (en) Combination therapy for treating cancer
CN120022281A (zh) Cdk4/6抑制剂的联用药物组合物及其用途
CN116159062A (zh) 药物组合物及其用途
WO2021160147A1 (zh) 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途
TW201521742A (zh) 具降低毒性之庫司替森（ｃｕｓｔｉｒｓｅｎ）療法
CN108836965A (zh) 尼克酰胺组合物在制备治疗索拉非尼手足皮肤反应药物中的应用
CN109106720B (zh) 西达本胺与依西美坦在制备用于治疗乳腺癌的联合用药物中的用途及联合用药物
CN107661324B (zh) 普罗帕酮在制备治疗食管癌药物中的应用
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
WO2018201920A1 (zh) 龙虎人丹在制备预防和/或治疗肝纤维化药物中的应用
CN109771437B (zh) 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用
TW202241421A (zh) 菸鹼醯胺及含有其的組合物的製藥用途
JPWO2022150628A5 (https=)